Loading provider…
Loading provider…
Hematology & Oncology Physician in Birmingham, AL
NPI: 1003122573Primary Employer
University of Alabama Health Services Foundation, PC.
uabmedicine.org
HQ Phone
Mobile
Get Amitkumar's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardAL State Medical License
AL State Medical License
AL State Medical License
2011 - 2025

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University of Alabama Medical Center
Fellowship • Hematology and Medical Oncology
2011 - 2014
Providence Hospital
Residency • Internal Medicine
2008 - 2011
Baroda Medical College
Medical School
Until 2002
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 163 | 290 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 84 | 136 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 31 | 31 |
| 4 | 99233Subsequent hospital inpatient care, typically 35 minutes per day | 20 | 79 |
| 5 | 99238Hospital discharge day management, 30 minutes or less | 11 | 11 |
Tivozanib: Status of Development
Authors: Amanda Hathaway
Publication Date: 2015-04
Treatment approaches of hard-to-treat non-Hodgkin lymphomas.
Authors: Lakshminarayanan Nandagopal, Amitkumar Mehta
Publication Date: 2017-02
Development and Integration of Antibody-Drug Conjugate in Non-Hodgkin Lymphoma.
Authors: Andres Forero-Torres
Journal: Curr Oncol Rep
Lead Sponsor: Bristol-Myers Squibb
Collaborators: Seagen Inc.
Intervention / Treatment: BIOLOGICAL: Nivolumab, DRUG: Brentuximab Vedotin
Lead Sponsor: Merck Sharp & Dohme LLC
Intervention / Treatment: BIOLOGICAL: pembrolizumab
Lead Sponsor: Pharmacyclics LLC.
Collaborators: AstraZeneca, Janssen Research & Development, LLC
Intervention / Treatment: DRUG: Ibrutinib, DRUG: MEDI4736